LakeShore Biopharma Updates on Former Chairman's Criminal Probe

TL;DR

LakeShore Biopharma (LAKESHORE) is under scrutiny due to a criminal probe involving its ex-chairman in China.

AI Summary

LakeShore Biopharma Co., Ltd. (formerly YS Biopharma Co., Ltd. and YishengBio Co., Ltd.) filed a 6-K on December 12, 2024, to provide an update on an ongoing criminal investigation in China involving its former chairman. The company's principal executive offices are located in Beijing, PRC.

Why It Matters

This filing signals potential legal and reputational risks for LakeShore Biopharma due to the criminal investigation involving a key former executive, which could impact investor confidence and future operations.

Risk Assessment

Risk Level: medium — The filing concerns a criminal investigation involving a former chairman, which can introduce legal, financial, and reputational risks.

Key Numbers

• 001-41598 — Commission File Number (Identifies the specific SEC filing series for LakeShore Biopharma.)

Key Players & Entities

• LakeShore Biopharma Co., Ltd. (company) — Registrant
• YS Biopharma Co., Ltd. (company) — Former Company Name
• YishengBio Co., Ltd (company) — Former Company Name
• 001-41598 (dollar_amount) — Commission file number
• December 2024 (date) — Reporting period
• Beijing, PRC (location) — Principal Executive Offices

FAQ

Filing Documents

• ea0224553-6k_lakeshore.htm (6-K) — 22KB
• 0001213900-24-108358.txt ( ) — 24KB

From the Filing

OF FOREIGN PRIVATE ISSUER UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2024 Commission file number: 001-41598 LAKESHORE BIOPHARMA CO., LTD (Exact name of registrant as specified in its charter) Building No. 2, 38 Yongda Road Daxing Biomedical Industry Park Daxing District, Beijing, PRC Tel: 010-89202086 (Address of Principal Executive Offices) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F Form 40-F LAKESHORE BIOPHARMA PROVIDES UPDATE ON ONGOING CRIMINAL INVESTIGATION INVOLVING FORMER CHAIRMAN IN CHINA LakeShore Biopharma Co., Ltd. (Nasdaq: LSB) (“LakeShore Biopharma” or the “Company”), a leading global biopharmaceutical company focused on the innovation and production of vaccines and therapeutic biologics for infectious diseases and cancer, today announced that the Shenyang Municipal Public Security Bureau in China (the “Bureau”) has initiated criminal investigations into actions taken by former chairman of the board of directors Yi Zhang (“Former Chairman”). Investigation Details : The Company has uncovered evidence suggesting that Yi Zhang, during his tenure in key executive roles, misappropriated corporate assets for personal gain and mismanaged the Company, resulting in significant financial losses over past several years, thereby seriously harming the interests of shareholders of the Company. Corrective Actions : In response to these revelations, by March 2024, the Company took decisive action to remove Yi Zhang from all executive positions within the Company and its subsidiaries, in accordance with the Company’s Memorandum and Articles of Association effective at that time and relevant laws. This action was necessary to mitigate the damage caused by Yi Zhang and his associates. Under the new leadership, the Company’s financial and operational performance has seen a marked improvement. The Company has achieved smooth operations, secured second position in China’s Rabies vaccine market and reaffirmed the full year financial guidance through Fiscal Year 2025 ended March 31, 2025. Recent Developments : In March 2024, Yi Zhang, despite having been dismissed, exploited his temporary control over the Company’s Seal to forge contracts and falsify debts to entities controlled by him. Using these documents, he initiated a case with the Kaifeng Arbitration Commission, leading to the freezing of assets and bank accounts of the Company’s wholly-owned subsidiary, Liaoning Yisheng Biopharma Co., Ltd., causing substantial operational challenges. Company Actions : The new management team swiftly secured additional financing to maintain business continuity and has taken comprehensive internal and external initiatives to reassure employees, customers, distributors, suppliers, and financial partners regarding the recent developments described above and to underscore the stability and ongoing operations of the business. The Company also promptly challenged the unfounded claims filed by Yi Zhang at the Kaifeng Arbitration Commission, and is confident that these baseless claims will be dismissed, allowing for the release of the frozen assets. Company Stance on Illegal Activities : LakeShore Biopharma will not condone the unlawful actions perpetrated by Yi Zhang during his tenure, nor the malicious damages inflicted subsequent to his removal. The Company is committed to firmly opposing any actions that could potentially undermine the Company’s operations and will vigilantly safeguard the interests of its shareholders. In light of this, the management team has lodged a formal report with the local government and the Bureau regarding these illegal activities. Following a thorough investigation and series of interrogations conducted over several months, the Bureau has communicated the following updates with the Company: 1. Sufficient evidence has been gathered to substantiate the criminal conduct of Yi Zhang, leading to the formal establishment of criminal cases against him; 2. Further corroboration is required, but given that Yi Zhang has absconded from China and is non-cooperative with the ongoing investigations, the Bureau is initiating procedures to issue an international arrest warrant; 3. The Bureau has pledged to assist the Company in resolving the matter pending before the Kaifeng Arbitration Commission. 1 Pursuing Legal Remedies : LakeShore Biopharma is actively contemplating legal proceedings against Yi Zhang aimed at securing compensation for the damages inflicted upon the Company and its shareholders. The Company will provide updates on the progress of these actions. Cautionary Statement Regarding Forward-Looking This current report

View Full Filing

View this 6-K filing on SEC EDGAR